Galapagos NV Earnings Call: Cash Rich, In Transition

Galapagos NV ((GLPG)) has held its Q4 earnings call. Read on for the main highlights of the call.

Galapagos NV’s latest earnings call painted a cautiously constructive picture, with management stressing a fortress-like near EUR 3.0 billion cash pile, a one-off return to operating profit, and a cleaner, more focused pipeline. Yet investors were repeatedly reminded that these positives are offset by hefty impairments, restructuring costs, and lingering execution risk as the company pivots away from cell therapy and leans harder into business development.

Robust cash position underpins strategic flexibility

Galapagos closed 2025 with approximately EUR 2,998 million in cash and financial investments, only modestly down year-on-year despite a major portfolio reset. Management framed this balance sheet strength as a key asset, providing ample firepower for business development and cushioning the impact of restructuring and wind-down charges expected over the next 18 months.

Headline operating profit masks non-recurring nature

The company swung to a 2025 operating profit from continuing operations of EUR 295.1 million versus a EUR 188.3 million loss in 2024, a dramatic turnaround on paper. However, executives emphasized this is largely an accounting outcome rather than an operational inflection, cautioning investors not to extrapolate the profit level into future years.

OLCA deferred income release boosts 2025 results

A central driver of the profit swing was the recognition of EUR 1,069 million in remaining deferred income from the Gilead OLCA, after concluding no outstanding obligations remained. Management noted that this sizeable uplift to operating profit comes without a corresponding cash tax impact, underscoring its one-time, non-cash nature.

TYK2 asset GLPG3667 delivers encouraging Phase II data

On the R&D front, Galapagos highlighted positive Phase II topline data for GLPG3667 in dermatomyositis, with the trial meeting its primary endpoint and showing meaningful benefit on secondary measures versus placebo. The company is now assessing strategic options, including potential partnerships, to accelerate and de-risk further development of this TYK2 program.

New leadership and refreshed board reshape governance

Management underscored that a largely new executive team is now in place, bringing extensive experience in transactions and capital deployment. Five new board directors have also joined, adding operational and deal-making expertise aimed at executing the revised strategy and sharpening oversight of capital allocation.

Disciplined BD strategy anchored in Gilead collaboration

The company outlined a more focused business-development approach centered on clinically de-risked assets in immunology, inflammation, and oncology. Gilead remains a key strategic partner, potentially sharing deal consideration and development costs, which could effectively enhance Galapagos’ purchasing power beyond its already significant cash balance.

Optimized currency mix enhances yield and flexibility

Management has shifted the cash mix to roughly 72% USD and 28% EUR, aligning liquidity with anticipated U.S.-heavy deal flow and cost base. This repositioning also targets higher yields, as the company highlighted around 4% returns on dollar holdings compared with roughly 2% in euros, improving overall interest income.

Restructuring cash burden trimmed but still sizeable

Galapagos cut its 2026 one-time restructuring cash guidance to a range of EUR 125–175 million, down from an earlier EUR 150–200 million forecast. While the reduction is welcome, executives made clear that the company still faces a meaningful near-term cash drain as it completes its strategic reset and organizational streamlining.

Cell therapy wind-down drives heavy non-operational charges

The decision to exit cell therapy came with substantial non-operational charges totaling EUR 399.8 million in 2025 operating expenses. These include impairments, severance, and early termination costs tied to collaborations, reflecting the scale of the shift away from the previously prioritized cell therapy franchise.

Material impairment underscores strategic pivot costs

Within those charges, an impairment of EUR 228.1 million related to cell therapy assets represented a major write-down for the year. Management framed this as the cost of sharpening focus, accepting a painful accounting reset in order to redeploy capital into more promising or de-risked opportunities.

Cash erosion highlights cost of transition

The company’s cash and financial investments declined from EUR 3,317.8 million at the end of 2024 to EUR 2,998 million at the end of 2025, a drop of about EUR 319.8 million or 9.6%. This movement reflects both ongoing operating expenditures and the financial impact of restructuring and wind-down activities as Galapagos reshapes its portfolio.

2026 to bring further restructuring cash outflows

Looking ahead, management expects up to EUR 50 million of operating cash outflow in Q1 2026 linked to the cell therapy wind-down. The company also flagged EUR 125–175 million in one-time restructuring cash costs, EUR 35–40 million to complete the January 2025 restructuring, and up to EUR 40 million to fund the TYK2 program during 2026.

Accounting-driven profit highlights underlying execution challenges

Executives repeatedly stressed that the 2025 operating profit is not evidence of a fully fixed business model but rather an accounting effect largely driven by the OLCA revenue release. This dynamic risks obscuring ongoing operational challenges, making execution on BD and pipeline decisions critical to generating sustainable earnings.

Unclear path forward for GLPG3667

Despite upbeat Phase II results, the company acknowledged that full data are still being collected and internally the bar for continued self-funding is high. Active discussions on partnership or other strategic routes leave uncertainty around the timing, design, and financial burden of a potential Phase III program for GLPG3667.

Valuation discount and credibility gap in investor base

Management openly addressed that Galapagos’ share price trades at a significant discount to its net cash, signaling skepticism about future value creation. Leadership framed closing this valuation gap as a near-term priority, hinging on visible BD execution, clearer capital allocation, and sustained engagement with shareholders.

Reliance on Gilead adds both leverage and dependence

While the Gilead partnership is pitched as a strategic advantage that can stretch Galapagos’ deal dollars, it also introduces a layer of dependence in structuring future transactions. Investors will be watching how the company balances this collaboration with the need to preserve strategic flexibility and negotiating power in upcoming deals.

Guidance signals cash discipline amid continued restructuring

Galapagos guided that the cell therapy wind-down should be largely completed by the end of Q3 2026, with significant but bounded cash outflows tied to restructuring and the TYK2 program. Despite these burdens, the company expects to be cash-flow neutral to slightly positive by year-end 2026 and projects an end-2026 cash and investment balance of about EUR 2.775–2.85 billion, excluding deal activity and currency swings.

Overall, the earnings call presented Galapagos as a company in transition, trading immediate pain for longer-term optionality backed by a strong cash reserve. Execution on business development, careful use of capital, and clarity on the future of GLPG3667 will likely determine whether the current discount to cash narrows or investors remain skeptical about the story.